• If you are wondering whether Regeneron Pharmaceuticals at around US$709.10 is priced attractively or already reflects the story, the valuation picture is where the answers start to emerge.
• The stock is up 0.3% over the last 7 days, while it shows a 6.7% decline over 30 days, an 8.7% decline year to date, and a 30.2% return over the past year, which can change how investors think about both upside potential and risk.
• Recent headlines around Regeneron often focus on its position within large cap biotech and its pipeline progress, which frame how investors interpret these mixed return figures. This backdrop helps explain why some see recent weakness as a pause, while others read it as a signal to reassess what the stock is worth.
• On Simply Wall St’s valuation checks, Regeneron scores a full 6 out of 6, and the next sections will walk through the main valuation approaches investors use for this stock, before finishing with a way to tie those numbers into a fuller view of value.

Approach 1: Regeneron Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today, using a required rate of return. For Regeneron Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections.

Regeneron’s latest twelve month free cash flow is about $3.9b. Analyst and extrapolated estimates used in the model reach a projected free cash flow of about $11.0b in 2035, with interim years such as 2026 and 2030 at $5.2b and $8.4b respectively. All of these cash flows are modeled in $ and then discounted back to today to arrive at an estimated intrinsic value per share.

On this basis, the DCF output suggests a fair value of about $2,092 per share, which is compared to the recent share price of around $709. This gap implies the stock is about 66.1% below the model’s estimate of intrinsic value. The DCF therefore indicates potential upside if the projections hold.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Regeneron Pharmaceuticals is undervalued by 66.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Regeneron Pharmaceuticals Price vs Earnings

For profitable companies like Regeneron Pharmaceuticals, the P/E ratio is a useful shorthand because it links what you pay for the stock to the earnings the business is currently generating. Investors usually accept a higher P/E when they expect stronger earnings growth or see lower risk, and a lower P/E when growth expectations are more modest or risks feel higher.

Regeneron’s current P/E is 16.3x, compared with the Biotechs industry average of about 17.8x and a peer average of 21.9x, so the stock is trading at a discount to both broad benchmarks. Simply Wall St’s Fair Ratio for Regeneron is 24.4x. This Fair Ratio is a proprietary estimate of what a reasonable P/E might be for the company, based on factors such as its earnings growth profile, profit margins, industry, market cap and specific risks.

Because the Fair Ratio folds these company specific drivers into a single reference point, it gives you a more tailored yardstick than a simple comparison with peers or the sector. With the Fair Ratio of 24.4x above the current 16.3x, the P/E based cross check points to the stock trading below that indicated level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Regeneron Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives take the DCF and P/E work you have just seen and add a simple story layer where you connect your view on Regeneron Pharmaceuticals, such as whether it deserves a Fair Value closer to the bullish US$1,057 target or the cautious US$730 target, to specific revenue, earnings and margin assumptions. You can then compare that Fair Value with the current price to help decide how attractive the stock looks. All of this is available inside an easy tool on Simply Wall St’s Community page that automatically refreshes when new news or earnings data arrive so your chosen Regeneron Pharmaceuticals Narrative is always aligned with the latest information.

Do you think there's more to the story for Regeneron Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.